The WHO’s SAGE has recommended the use of Takeda’s QDENGA in high dengue burden and transmission areas. Credit: Michael Vi/Shutterstock.com.

The World Health Organisation’s (WHO) Strategic Advisory Group of Experts (SAGE) has recommended Takeda’s QDENGA (dengue tetravalent vaccine [live, attenuated]) for use in high dengue burden and transmission areas.

The SAGE recommendation will be considered by the WHO in the coming months. It will update the position paper on dengue vaccines to include final guidance on QDENGA’s use in public vaccination programmes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

SAGE recommendations include the introduction of the vaccine in settings with high dengue disease burden and high transmission intensity to increase the public health impact and lower any potential risk in seronegative populations.

It has also recommended the usage of QDENGA for children aged between six and 16 years. For this age group, the vaccine should be introduced one to two years before the age-specific peak incidence of hospitalisations due to dengue.

The vaccine must be given in a two-dose schedule with a three-month interval between doses.

See Also:

Introduction of the vaccine requires a well-designed communication strategy and community engagement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SAGE assessed data across 19 Phase I, II and III studies of more than 28,000 adults and children, including the pivotal Phase III Tetravalent Immunisation against Dengue Efficacy Study (TIDES) trial. This study was in line with WHO guidance for a second-generation dengue vaccine.

The trial attained its primary endpoint of overall vaccine efficacy against virologically confirmed dengue with an efficacy of 80.2% for 12 months. It achieved all secondary endpoints during an 18-month follow-up period.

Takeda Global Vaccine Business Unit president Gary Dubin stated: “The global impact of dengue cannot be overlooked as the incidence continues to rise. This week, the World Health Organisation’s SAGE provided important recommendations for the use of QDENGA in preventing dengue.”